Difference between revisions of "Denileukin diftitox (Ontak)"
Jump to navigation
Jump to search
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
(updated content) |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Recombinant diphtheria toxin fusion protein which binds with high affinity to IL-2 receptors. The fusion protein is internalized by receptor-mediated endocytosis and is cleaved, releasing the diphtheria toxin, which inhibits protein synthesis and causes cell death.<ref name="insert">[http://www.ontak.com/PDFs/PI_Ontak.pdf Denileukin diftitox (Ontak) package insert]</ref><ref>[ | + | Class/mechanism: Recombinant diphtheria toxin fusion protein which binds with high affinity to IL-2 receptors. The fusion protein is internalized by receptor-mediated endocytosis and is cleaved, releasing the diphtheria toxin, which inhibits protein synthesis and causes cell death.<ref name="insert">[http://www.ontak.com/PDFs/PI_Ontak.pdf Denileukin diftitox (Ontak) package insert]</ref><ref>[[Media:Denileukindiftitox.pdf | Denileukin diftitox (Ontak) package insert (locally hosted backup)]]</ref><ref>[http://www.ontak.com/ Ontak manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *Cutaneous T-cell lymphoma (CTCL) | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http:// | + | *[http://chemocare.com/chemotherapy/drug-info/denileukin-diftitox.aspx Denileukin diftitox (Ontak) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/denileukin-diftitox.aspx Denileukin diftitox (Ontak) patient drug information (Chemocare)]</ref> |
| + | *Brief patient counseling information can be found on [http://www.ontak.com/PDFs/PI_Ontak.pdf#page=5 page 5 of the Denileukin diftitox (Ontak) package insert]<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/denileukin-diftitox-patient-drug-information Denileukin diftitox (Ontak) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/denileukin-diftitox-patient-drug-information Denileukin diftitox (Ontak) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/denileukin-diftitox-patient-drug-information Denileukin diftitox (Ontak) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/denileukin-diftitox-patient-drug-information Denileukin diftitox (Ontak) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Immunotherapy]] | ||
| + | [[Category:Non-Hodgkin lymphoma medications]] | ||
Revision as of 19:52, 14 October 2012
General information
Class/mechanism: Recombinant diphtheria toxin fusion protein which binds with high affinity to IL-2 receptors. The fusion protein is internalized by receptor-mediated endocytosis and is cleaved, releasing the diphtheria toxin, which inhibits protein synthesis and causes cell death.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Cutaneous T-cell lymphoma (CTCL)
Patient drug information
- Denileukin diftitox (Ontak) patient drug information (Chemocare)[4]
- Brief patient counseling information can be found on page 5 of the Denileukin diftitox (Ontak) package insert[1]
- Denileukin diftitox (Ontak) patient drug information (UpToDate)[5]